LONDON, Dec 30: Britain on Wednesday became the first country in the world to approve a coronavirus vaccine developed by Oxford University and AstraZeneca as it battles a major winter surge driven by a new, highly contagious variant of the virus.
AstraZeneca said the authorisation was for a two dose regime and that the vaccine had been approved for use for emergency supply. Britain has ordered 100 million doses of the vaccine.
“The government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca’s COVID-19 vaccine for use,” the health ministry said.
Britain is already rolling out the Pfizer-BioNTech vaccine. In a change of approach, the Joint Committee on Vaccination and Immunisation (JCVI) said the priority should be to give as many people in at-risk groups their first dose, rather than providing the required two doses in as short a time as possible.
First human trial of AstraZeneca COVID-19 vaccine shows promise
Health minister Matt Hancock said the MHRA would set out more details on the dosing regimen later on Wednesday.
Regulatory endorsement is a welcome boost for AstraZeneca and the Oxford team, which have been accused of a lack of clarity about the results from late-stage trials.
“Today is an important day for millions of people in the UK who will get access to this new vaccine,” AstraZeneca Chief Executive Pascal Soriot said. “It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit”
Pooled results from those trials show it had overall efficacy of 70.4%. Efficacy was 62% for trial participants given two full doses, but 90% for a smaller sub-group given a half, then a full dose.
Researchers said that the finding of 90% efficacy for the low-dose/high-dose regime needed more investigation. AstraZeneca did not specify which dose regime had been approved.
“To get out of this debacle there is no alternative to having a significant majority of the population carrying a high level of neutralising antibodies. With today’s announcement that comes within our grasp,” said Danny Altmann, a professor of immunology at Imperial College London.
“I suspect this will speed things by several months. An immune population by the spring starts to look feasible.”
The pandemic has already killed 1.7 million people around the world, sown chaos through the global economy and upended normal life for billions since it began in Wuhan, China, a year ago.
Britain and South Africa in particular are grappling with new variants of the coronavirus, which the government and scientists say are more contagious. Many countries have responded by banning passenger flights and blocking trade.
AstraZeneca and other developers have said they are studying the impact of the new variant but expect that their shots will be effective against it.
